You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

The Role of Bisphosphonates in the Management of Skeletal Complications for Patients with Multiple Myeloma

ID: 6-4 Oct 2012
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Hematology Disease Site Group

Patient Population

Adult patients with active plasma cell myeloma (symptomatic stage 1 or greater).

Research Question(s)

For patients with active multiple myeloma, is there evidence that the use of bisphosphonates:

  1. Improves survival?
  2. Improves quality of life?
  3. Reduces bone pain?
  4. Reduces or delays the development of skeletal complications? 
  5. For patients with multiple myeloma who receive treatment with a bisphosphonate:
  6. What is the association of bisphosphonates with osteonecrosis of the jaw (ONJ)? 
  7. How can this complication be prevented and managed?
pdf download Summary (PDF) (229.04 KB)
pdf download Full Report (PDF) (672.11 KB)